Author

C. Foret-Lucas

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:host-pathogen & immune response· 3 Organism:Drosophila· 2 Assay:proteomics· 2 Organism:chicken / avian· 1 Organism:mouse· 1

Frequent Co-Authors

A. Coggon· 2 shared J.-L. GUERIN· 2 shared P. Bessiere· 2 shared R. Volmer· 2 shared T. Figueroa· 2 shared A. Houffschmitt· 1 shared A. Perlas· 1 shared A. Secula· 1 shared

Activity by Year

2021-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 27 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersMicrobiology

A. Coggon

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

The Feather Epithelium Contributes to the Dissemination and Ecology of clade 2.3.4.4b H5 High Pathogenicity Avian Influenza Virus in Ducks

N. Gaide, F. Filaire, K. Bertran, M. Crispo, M. Dirat, A. Secula, C. Foret-Lucas, B. Payre, A. Perlas, G. Cantero, N. Majo, S. Soubies, J.-L. GUERIN

This study shows that the feather epithelium in ducks supports viral replication and releases infectious virions, contributing to environmental spread of H5 HPAIVs.

bioRxiv · Jul 26, 2023 · PreprintMicrobiology

Host factors drive the within-host competition between highly and low pathogenic H5N8 avian influenza viruses

P. Bessiere, T. Figueroa, A. Coggon, C. Foret-Lucas, A. Houffschmitt, M. Fusade-Boyer, G. Dupre, J.-L. Guerin, M. Delverdier, R. Volmer

The paper investigates how host factors influence the competition between low and high pathogenic H5N8 avian influenza viruses, showing differential outcomes in chickens and ducks.

bioRxiv · Apr 6, 2021Microbiology

Intranasal type I interferon treatment is beneficial only when administered before clinical signs onset in the SARS-CoV-2 hamster model

P. Bessiere, M. Wasniewsk, E. Picard-Meyer, A. Servat, T. Figueroa, C. Foret-Lucas, A. Coggon, S. Lesellier, F. Boue, N. Cebron, B. Gausseres, C. Trumel, G. Foucras, F. J. Salguero, E. Monchatre-Leroy, R. Volmer

This study shows that intranasal type I interferon treatment is effective only when given before clinical signs onset in a SARS-CoV-2 hamster model, not after symptoms appear.

bioRxiv · Feb 9, 2021Microbiology